Pharma BD Deal Intelligence
A $960M all-cash acquisition that gave Lilly the migraine drug lasmiditan, expanding its neuroscience pipeline into acute migraine treatment. The deal closed cleanly, though lasmiditan's commercial performance since launch has been modest against a crowded CGRP-inhibitor field.
Lilly acquired CoLucid for $960M for migraine therapy lasmiditan.
$3.9B US Migraine Market (2017) · ~50% Patients Dissatisfied with Triptans
Migraine affects ~39M Americans. Lasmiditan was the first drug in the ditan class (5-HT1F agonists), offering a non-vasoconstrictive alternative to triptans for patients with cardiovascular risk.
Lasmiditan (Reyvow) was approved in 2019 as the first 5-HT1F agonist. Commercial uptake was limited by CNS side effects and Schedule V designation.
Eli Lilly and Company completed a acquisition/merger transaction with CoLucid Pharmaceuticals.
Significant transaction at $960M. Lilly acquired CoLucid for $960M for migraine therapy lasmiditan.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / CoLucid Pharmaceuticals (this deal) | 2017 | $960M | 57 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2017 deals · Eli Lilly and Company deals · Neurology deals